Cost–Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.